PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.
Employees: 11-50
Total raised: $65M
Investors 1
| Date | Name | Website |
| 13.11.2023 | LionBird | lionbird.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.05.2025 | Series A | $50M | - |
| 31.10.2023 | - | $15M | - |
Mentions in press and media 11
| Date | Title | Description |
| 19.05.2025 | PhaseV: $50 Million Series A Closed For Clinical Development Platform | PhaseV, a leader in AI/ML-driven clinical development, announced the completion of a $50 million Series A funding round. The round was co-led by Accel and Insight Partners, and existing investors Viola Ventures, EXOR, and LionBird participa... |
| 14.05.2025 | PhaseV's $50M Funding: A Leap into AI-Driven Clinical Trials | In the world of pharmaceuticals, time is money. Every day spent in clinical trials can cost millions. Enter PhaseV, a Boston-based company that just secured $50 million in Series A funding. This investment is a game-changer. It positions Ph... |
| 13.05.2025 | PhaseV scores $50M for AI clinical trial platform | Photo: sanjeri/Getty Images Israeli startup PhaseV, an AI-enabled clinical development company for life sciences, has secured $50 million in Series A funding in a round co-led by Accel and Insight Partners. Existing investors Viola Ventures... |
| 13.05.2025 | PhaseV Raises $50M in Series A Funding | PhaseV, a Boston, MA-based company which specializes in AI/ML-driven clinical development, raised $50M in Series A funding. The round was co-led by Accel and Insight Partners with participation of existing investors Viola Ventures, EXOR and... |
| 13.05.2025 | PhaseV Closes $50M to Advance AI Clinical Development | What You Should Know: – PhaseV, a company at the forefront of applying artificial intelligence (AI) and machine learning (ML) to clinical development raies $50M in Series A funding round co-led by Accel and Insight Partners, with participat... |
| 07.11.2023 | 9xchange Biopharma Marketplace Partners with PhaseV to Bring ML-Powered Clinical Trial Optimization Technology to Ecosystem Members | The 9xchange platform releases drugs from owners who are unlikely to pursue them further, while providing access to the right AI/ML technologies to unleash new value PhaseV, a pioneer in causal machine learning (ML) for dynamic clinical tri... |
| 31.10.2023 | PhaseV Raises $15M for ML-Driven Clinical Trial Optimization | What You Should Know: PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 million in funding, led by Viola Ventures and Exor Ventures, includi... |
| 24.10.2023 | PhaseV reaps $15M in funding to streamline trial design with machine learning | PhaseV, which uses machine learning to help design clinical trials, received a $15 million funding shot in the arm to expand its offerings and global reach. The Boston- and Tel Aviv-based company's platform allows clinical development teams... |
| 24.10.2023 | PhaseV Raises $15M Funding | PhaseV, a Tel Aviv, Israel and Boston, MA-based company which specializes in causal machine learning (ML) technology that optimizes clinical trial design and analysis, raised $15M in funding. The round was led by Viola Ventures and Exor Ven... |
| 24.10.2023 | PhaseV Nabs $15M | BOSTON, MA, PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 million in funding. >> Click here for more funding data on PhaseV &g... |
Show more